(Q45051268)
Statements
1 reference
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients (English)
1 reference
Robin Wood
1 reference
Joseph Eron
1 reference
Keikawus Arasteh
1 reference
Eugenio Teofilo
1 reference
Christian Trepo
1 reference
Jean-Michel Livrozet
1 reference
Jane Yeo
1 reference
Judith Millard
1 reference
Mary Beth Wire
1 reference
Odin J Naderer
1 reference
26 July 2004
1 reference
1 reference
39
1 reference
4
1 reference
591-594
1 reference
Identifiers
1 reference
1 reference